Inozyme Pharma (NASDAQ:INZY) Announces Earnings Results

Inozyme Pharma (NASDAQ:INZY) released its quarterly earnings results on Tuesday. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05, Zacks reports.

Inozyme Pharma Price Performance

INZY traded down $0.04 on Thursday, hitting $4.19. 218,480 shares of the company were exchanged, compared to its average volume of 417,269. The company has a debt-to-equity ratio of 0.48, a quick ratio of 9.84 and a current ratio of 9.84. The business’s fifty day moving average is $5.15 and its 200 day moving average is $4.93. Inozyme Pharma has a fifty-two week low of $2.71 and a fifty-two week high of $7.80. The firm has a market capitalization of $262.84 million, a P/E ratio of -2.90 and a beta of 1.54.

Wall Street Analyst Weigh In

INZY has been the topic of several research analyst reports. Stifel Nicolaus started coverage on Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday. Jefferies Financial Group restated a “buy” rating and set a $17.00 price objective (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Wedbush restated an “outperform” rating and set a $12.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a research report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a research report on Wednesday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $15.71.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.